Kardigan (KARD) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kardigan is the larger company by market cap ($1.29 billion vs $1.24 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KARD | ORIC |
|---|---|---|
| Share price | $13.83 | $12.01 |
| Market cap | $1.29B | $1.24B |
| 1-day change | +2.52% | +0.25% |
| YTD return | — | +46.82% |
| 1-year return | — | -14.94% |
| 5-year return | — | -26.00% |
| EPS (TTM) | $-10.93 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.00 | $14.68 |
| 52-week low | $12.32 | $7.23 |
| Distance from 52-week high | -48.78% | -18.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +205.50% | +78.43% |
| Average volume | 477.59K | 1.47M |
| Shares outstanding | 93.50M | 103.65M |
| Employees | 241 | 111 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kardigan
KARD stock →Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
Healthcare · Biotechnology · 241 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Healthcare · Biotechnology · 111 employees
KARD vs ORIC FAQ
Which is bigger, Kardigan or Oric Pharmaceuticals?
Kardigan (KARD) is larger, with a market capitalization of $1.29B compared with $1.24B for Oric Pharmaceuticals (ORIC).
Are Kardigan and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.